Current PCA Methods
A gap exists between what is available and what is needed and can be supplied. Current pain amelioration is rated on a scale of one to five. Devices at present are at about level 2.00.
The Cade technology is a development in bridging this gap and will take the standard to about four and a half. Existing devices can be upgraded by this technology; obviating the need for a total upgrade.
The market is led by the clinical acceptance of the technology.
Note: Existing units available in the market do not offer “intelligent” feedback control and are sold to the hospitals at prices similar to the intended sale price of the Mondo unit.
Adaptive PCA Benefits
The Mondo Medical PCA products will be the first of their kind in the world and there is a significant cost cutting benefit to hospitals that install them. They fit perfectly with the new trend to telemedicines.
The unique benefits of the adaptive PCA technology put these devices streets ahead of any alternatives.
The Cade devices can be introduced without the usual ‘Barriers to Entry’ due to:
- Self determined and self assessed(by the patient) pain control.
- An ‘intelligent sytem’ of pain control leading to faster recovery and the savings that creates.
- Ability to remote monitor patient drug usage - with savings that creates.
- Data recording for drug trials - reducing risk of human error.
- Capability of connecting with other computer based systems, creating more efficiencies.
- Flexibility to add functions such as Cardiograph - additional servicing at the time.
- Improved efficiency of hospital staff through connection of the system to a computer network - and the saving this will create.
- Automatic weaning off the drugs prescribed.
The Cade device fits perfectly into the current economic environment requiring fewer hospital bed days per patient, while maintaining comprehensive and appropriate treatment. This economic restraint has resulted in the hospitals driving the development of devices like the adaptive PCA. This economic thrust is apparent in all Western economies.
- Minimal training and expense. Distributors will provide training as part of the purchase price but this technology reduces ‘hands on’ requirement of training for operators.
- Ease of use; design and function incorporate user friendly principles. The algorithm replaces manual activity of highly trained nursing staff, or complements existing high standards.
- Minimal programming and supervision by staff.
- Software based ‘Best Practice’ principles.
- Capital cost in line with current machines, equating to large future saving. The reduced expenses through labour savings, elimination of drug misuse, waste reduction and the reduced chance of litigation as the algorithm provides more accurate treatment.
- Earlier patient discharge - fewer bed days per patient, through exact prescription and automatic drug weaning, improved healing in a pain free state.
- Off site treatment and monitoring, through remote supervision, ie. telemedicine.
- Compatibility with existing technology enabling upgrades by adding the controller and sensors to an existing pump unit, as an option to supplying the whole device.
The second generation device will have remote monitoring capability, compact size and automatic operation, it can be used in the patient’s home (or nursing home), paving the way for the private and nursing home market.
The patient controlled analgesia is unique because it is the only device available at present that modifies its delivery parameters according to the changing physical needs of the patient. Furthermore, as it is in effect a pump controller, it can be retro fitted to existing infusion pumps currently in use. It allows update by addition, not by replacement.